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Editorial
Influenza Pandemic AH1N1v/2009 – early experience 
and autumn perspectives
P. Crovari, r. GasParini
Department of Health sciences, Genoa University, italy
Between end of March and early april 2009, a novel in-
fluenza a H1n1 virus of swine origin spread in Mexico 
and in the United states of america [1]. Within a few 
weeks, the virus was circulating throughout the world 
(118 Countries by 29th June). since its transmission is 
direct from man to man, the WHo raised a pandemic 
alarm, initially at level 4 and, soon after, at levels 5 and 
6 (11.6.2009).
This virus has the potential to cause the first influenza 
pandemic of the XXist Century. 
The first few months of observation and research have 
highlighted some important points, especially concern-
ing the agent at work and its origin. The data that have 
been collected indicate that the new viral strain has 
originated from reassortments, occurring in swine, be-
tween two viruses, which had been present in the same 
animal for some time [2, 3]:
• a swine strain, aH1n1, derived from a triple reas-
sortment, exhibited in its genome segments of rna 
of human and avian origin. This virus has circulated 
in american pigs for approximately 10 years, with-
out creating any particular problems to either swine 
or man [4].
• another swine strain, aH1n1, of the Euro-asiatic 
lineage, has caused limited outbreaks in European 
and asian pig farms for some time.
Even if the origin and characterization of the new virus 
has been characterized, the mechanism leading to it be-
ing adapted to man still remains to be defined. 
some useful information has also been generated on the 
possible severity of the pandemic.
Even if the data collected so far relate to a limited 
number of cases, according to the evaluation parameters 
indicated by WHo [5, 6] this pandemic should be of 
“moderate” severity.
it is likely that a virus, similar to the new H1n1, had 
previously circulated in the world population during 
the thirties and fifties of last century. accordingly, ap-
proximately 30% of subjects over 60 years of age have 
detectable antibodies against the novel virus [7]. it has 
also been found that vaccination with the seasonal tri-
valent vaccines (containing aH1n1 virus strains, which 
circulated in the first few years of this century) has not 
provided protection against the new viral variant [7].
The novel virus is sensitive to neuroaminidase inhibitor 
drugs (Tamiflu and relenza) and resistant to M2 in-
hibitors (amantadanes) [8]. From this point of view, the 
new H1n1 variant is clearly different from the seasonal 
H1n1 strains, that was resistant to Tamiflu (99%) and 
sensitive both to relenza, and M2 inhibitors [8].
From an epidemiological perspective, different scenar-
ios have been observed. in north america an epidemic 
peak of the disease occurred end of spring-early in 
summer, with a pattern similar to a seasonal peak. now 
the epidemic continues to increase in the Western area 
of the United states, but has started to decrease in sev-
eral other areas [8]. in Europe, even if cases have been 
recorded in almost every Country, a community spread-
ing and, consequently, an epidemic peak, has been ob-
served only in the United Kingdom [9]. in the southern 
Hemisphere (argentina, Chile, australia, etc.), where 
winter is just starting, the H1n1v influenza is rapidly 
spreading [10].
it will be important to follow the course of this “new” 
influenza in countries in the southern hemisphere, 
where the climate factor plays in favour of the virus, as 
it could offer useful information applicable to issues that 
at present are unresolved.
• Will the new H1n1 strain replace on the epidemio-
logical scene the strain that has circulated until now 
(and which is present in the seasonal vaccine)?
• Will adaptation of the new virus to man remain 
unchanged, i.e., will its “reproduction rate” increase 
with time?
• Will the severity of the pandemic, and in particular 
its case fatality ratio, increase with the increase in 
human transmission of the virus and the spread of 
the disease?
• Will the sensitivity of the new virus to the antiviral 
drugs remain unchanged? 
• Who will win the race between the virus and the 
producers of its specific vaccine, so that at least in 
some areas of the World, a significant amount of the 
population could be immunized prior to the epidemic 
wave?
if there are no sudden changes, which are always pos-
sible with influenza viruses, it is quite likely that the 
autumn-Winter of 2009-2010 will represent a test 
bench for the northern Hemisphere, not only for the 
pathogenic potential of the novel H1n1, but also for 
the capability of developed countries to face a new 
influenza pandemic. in this respect, we must consider 
that, for the first time in history, many countries face 
an influenza pandemic (a) with a detailed plan of 
preparedness and control, (b) with new arms, such as 
anti-viral drugs and vaccines, and (c) a sophisticated 
communications system. The risk of using our arms 
improperly requires a truly global approach to this 
global challenge.
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